The global cellular pathology market was valued at USD 32.7 Billion in 2022 and is expected to reach USD 78.3 Billion by 2033. The services with around 48.0% value share, has topped the global market within the product and services category in 2022 and is expected to grow at a CAGR of close to 7.5% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 32.7 Billion |
| Market Value 2023 | USD 35.2 Billion |
| Market Value 2033 | USD 78.3 Billion |
| CAGR 2023 to 2033 | 8.3% |
| Market Share of Top 5 Countries | 57.4% |
| Key Market Players | Leica Biosystems, Nussloch GmbH (Danaher Corporation), BioGenex. Hologic, Inc., Epredia, Sakura Finetek, F. Hoffmann-La Roche Ltd., Merck KGaA, Gestalt Diagnostics, Carl Zeiss AG, Olympus Corporation, Abbott Laboratories, Inc., and NeoGenomics Laboratories. |
Cellular pathology is a branch of medicine that studies organs and tissues, diagnosing illnesses and medical problems. It enables high-resolution anatomic assessment of phenotypes, enabling histology to discern diagnostic and characteristic cellular changes in diseased tissues. This interpretative power is evident in every major human disease, relying on unbiased pan-cellular staining.
The COVID-19 pandemic led to the replacement of traditional cellular pathology reporting with personal microscopes and connected monitors. Oncology workflows use complex biomarkers, requiring tumor tissue for decision-making, requiring time and resources. AI's potential in computer vision applications has led to opportunities in digital pathology, but challenges remain.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global market for cellular pathology was around 9.8% of the overall USD 9.56 Billion of the global pathology laboratories market in 2022.
The COVID-19 pandemic had a huge influence on health care, resulting in a move away from multiheaded microscopes and toward personal microscopes and linked monitors for histopathology reporting. Technological advances and new information have had a tremendous influence on how medicine and health care are practiced and delivered. These developments have had an influence on clinical services such as radiography and pathology, necessitating new trends and problems in service delivery.
The increase in prevalence of chronic disorders has led to rise in demand for diagnostic services, including cytopathology. As the number of individuals with chronic disease continue to grow, there is greater need for accurate and timely diagnoses to guide appropriate treatment plans.
The increased prevalence has resulted in higher demand for pathology lab services, including histology. Pathology labs play a crucial role in diagnosing and monitoring chronic diseases, as they provide valuable insights into the cellular and molecular changes occurring in the body. Cellular pathology helps identify tissue abnormalities at cellular level, aiding in accurate diagnosis and staging of diseases. Owed to the above factors, the global market is projected to grow at CAGR of 8.3% in forecasted period.
Pathology practice has seen a rise in demand for diagnostic pathology services, as well as improvements in turnaround time and adherence to laboratory accreditation and quality assurance regulatory agencies. These improvements have also been aided by sub-specialization, interdisciplinary team meetings, and advances in information technology and digital imaging.
Patients and healthcare professionals are becoming increasingly aware of the value of early and precise diagnosis. Patients are taking more active role in taking control of their health and seeking prompt medical attention. The importance of cellular pathology in making accurate diagnoses and directing treatment choices is also becoming recognized by healthcare practitioners.
Growing market consolidation actions have been observed in the cellular pathology sector, with bigger pathology service providers purchasing smaller, specialized laboratories. The combination of cutting-edge technology and knowledge made possible by this consolidation has also made cellular pathology testing more precise and effective.
Cellular pathology market growth has been attributed to a number of factors, including an increase in the prevalence of chronic diseases, a preference for path lab services, growing public awareness of the value of cellular pathology, and market consolidation activities. This trend is expected to continue as long as there is a demand for accurate and timely diagnostic services.
As a result of growing demand, adherence to cancer case reporting rules, better turnaround time, laboratory accreditation, and quality assurance requirements, clinical pathology services are confronting problems. Sub-specialization, interdisciplinary team meetings, a drop in autopsies, fast breakthroughs in procedures, and advances in information technology and digital imaging are putting pressure on cellular pathology. Pathology services must adapt to new trends, a rising number of biopsies, and emerging procedures in order to satisfy these needs.
For proper diagnosis and testing, the cellular pathology industry relies on innovative technologies and equipment. However, these technologies frequently come at a cost. Acquiring and maintaining modern instruments, such as digital imaging systems and automated slide scanners, may be expensive. Smaller pathology labs and healthcare organizations with limited finances have a problem in investing in these technologies. The high cost may also result in higher service charges for patients, limiting access to cellular pathology services.
Strict regulatory criteria maintain patient safety and diagnostic accuracy in the cellular pathology sector. Guidelines and standards for laboratory techniques, quality control, and proficiency testing are imposed by regulatory organizations. Compliance with these regulations can be complicated and time-consuming, necessitating the use of specialized resources and experience. Small laboratories with minimal resources may struggle to meet regulatory standards. These constraints underscore the difficulties that the cellular pathology market is facing.
The USA occupies 91.1% value share in North America in 2022. Chronic illnesses can cause mortality, hospitalization, and impaired quality of life, making them the greatest cause of death and disability in the United States. Cellular pathology plays important role in diagnosis of these illnesses, this makes USA prominent market for cellular pathology in North America.
India expenditure on cellular pathology in 2022 was USD 2.3 Billion.
The risk increases proportionally to the intensity and duration of exposure to each carcinogen. The prevalence of cancer is associated with poor hygiene, diet, or viral infections.
Individual susceptibilities to these risk factors vary within the general population, and site-specific data from different parts of the country provide clues to the etiological factors responsible for this significant variation. Diagnosis of the disease is required; cellular pathology laboratories fill the gap and aid in prompt detection. As a result, India is a lucrative market for the cellular pathology industry.
In 2022, the Germany held a dominant global revenue in the Europe market and contributed around USD 1.9 Billion.
By using augmented reality microscopy, areas suspicious of tumors are marked in the pathologist's field of view using a light pointer. Similar approaches are being pursued in clinical decision support systems. AI-assisted approaches are being evaluated in Germany, with products designed for routine diagnostics in radiology and pathology. As a result of technological advancements, Germany has become a significant market for cellular pathology.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
By product and services, services section covered 48.0% market shares in world in 2022. Pathology services in high-income countries involve various disciplines and sub-specialties, divided into clinical pathology and anatomic pathology. These services are provided through central laboratories, smaller laboratories in rural environments, and small laboratories in conjunction with university departments.
Central laboratories provide infrastructure, specimen collection services, transport, reception, and electronic patient records, while smaller laboratories offer limited tests and point-of-care testing. These laboratories also undertake research and provide education and training in pathology and related disciplines. Thus cellular pathology diagnosis services are predicted to expand rapidly between 2023 and 2033.
The market value of disease diagnosis in cellular pathology is USD 16.2 Billion, representing for a sizable 49.5% market share in 2022.
Pathology is critical in disease monitoring, detecting new illnesses, maintaining disease registries, and assisting with clinical care. It aids in determining illness severity and prognosis, as well as dictating treatment options for patients and evaluating clinical response. However, when non-communicable illnesses grow more common, the rate of misdiagnosis may increase, resulting in wasted deaths, protracted suffering, and societal disturbance. A lack of data for illness surveillance and registries impedes public policy and resource allocation. Hence disease diagnosis in cellular pathology is preferred prominently.
The hospitals have a considerable presence in the cellular pathology market, accounting for 46.9% of end users in 2022, and exhibiting a high CAGR of 7.5% over the forecast period.
In high-income nations, hospital pathology services are often supplied by central laboratories with shared equipment and computerized patient data.
Collaborations and partnership among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten cellular pathology. Collaboration in research, development, and commercialization leads to market expansion and the creation of new applications. Numerous large firms compete in the field of cellular pathology. Among the well-known players in this field are:
Similarly, recent developments related to the company’s providing the cellular pathology services have been tracked by the team at Future Market Insights, which are available in the full report.
| Attributes | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2016 to 2022 |
| Market Analysis | USD Million for Value, Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Vietnam Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Product & Services, Application, End User, and Region |
| Key Companies Profiled | Leica Biosystems Nussloch GmbH (Danaher Corporation); BioGenex; Hologic, Inc.; Epredia; Sakura Finetek; F. Hoffmann-La Roche Ltd.; Merck KGaA; Gestalt Diagnostics; Carl Zeiss AG; Olympus Corporation; Abbott Laboratories Inc.; NeoGenomics Laboratories |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market acquired USD 32.7 billion in 2022.
Pathology services in high-income countries are likely to expand significantly.
India is estimated to hold a 6.9% market share in 2022.
Germany accounted for a market share of 5.9% in 2022.
The global market expanded at a CAGR of 6.6% between 2018 and 2022.
| Market Estimated Size in 2023 | USD 7,035.8 million |
|---|---|
| Projected Market Value in 2033 | USD 24,961.8 million |
| Value-based CAGR from 2023 to 2033 | 13.5% |
| CAGR (2023 to 2033) | 9.7% |
|---|---|
| Market Size (2023) | USD 776.8 million |
| Market Size (2033) | USD 1962.2 million |
| Market Size (2022) | USD 971.59 Million |
|---|---|
| Market Size (2032) | USD 2603.74 Million |
| Market CAGR (2022 to 2032) | 10.36% |
Explore Life Science & Biotechnology Insights
View Reports
Cellular Pathology Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
